Charles Schwab Investment Management Inc Macrogenics Inc Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 334,349 shares of MGNX stock, worth $648,637. This represents 0.0% of its overall portfolio holdings.
Number of Shares
334,349
Previous 525,535
36.38%
Holding current value
$648,637
Previous $667,000
39.43%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding MGNX
# of Institutions
117Shares Held
52.3MCall Options Held
55.3KPut Options Held
35.9K-
Bellevue Group Ag Kuesnacht, V89.92MShares$19.2 Million0.27% of portfolio
-
Armistice Capital, LLC New York, NY5.96MShares$11.6 Million0.13% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$10.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.21MShares$8.17 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$6.31 Million0.02% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $119M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...